SpyGlass posts 12-month BIM-IOL results

SpyGlass Pharma’s latest glaucoma update is about a cataract-surgery implant that is also designed to deliver medicine for a year. The company said March 9 that its phase 1/2 trial of the BIM-IOL System met 12-month efficacy and safety goals in patients with open-angle glaucoma or ocular hypertension who were also undergoing cataract surgery. Ophthalmology Times published a summary of the data on June 3, citing sustained intraocular-pressure reduction, high rates of drop-free control and favorable visual outcomes. ### What exactly is the BIM-IOL System? The BIM-IOL System is a monofocal intraocular lens with two non-bioerodible drug pads attached at the optic-haptic junction, according to SpyGlass and Ophthalmology Times. The lens is implanted during routine cataract surgery, and the pads are designed to elute bimatoprost over time. (ophthalmologytimes.com) SpyGlass is developing the product for patients who already need cataract surgery and also have elevated intraocular pressure from open-angle glaucoma or ocular hypertension. Malik Kahook, SpyGlass’s chief medical officer and executive chair, said the aim is to reduce pressure while removing the need for chronic topical drops. (ophthalmologytimes.com) ### What did the 12-month trial show? The phase 1/2 study enrolled 104 patients and randomized them 2:1:1 to a 78-mcg BIM-IOL dose, a 39-mcg dose or control cataract surgery, according to the company’s release and follow-up trade coverage. The 78-mcg commercial dose group showed a 34% mean reduction in intraocular pressure from baseline at the 12-month 8 a.m. timepoint, while the 39-mcg group showed a 42% reduction and the control group showed a 35% reduction. (ir.spyglasspharma.com) At 12 months, 98% of evaluable patients in the 78-mcg group were free from all topical pressure-lowering medications, SpyGlass said in March and reiterated in its May corporate update. Ophthalmology Times also reported preserved visual acuity and contrast sensitivity, with no adverse event pattern that the company said would alter the known cataract-surgery safety profile. (ir.spyglasspharma.com) ### Why is the “drop-free” result getting attention? Glaucoma treatment often depends on long-term adherence to daily eye drops, and that has been a persistent problem in ophthalmology. Kahook said the 12-month results suggest the implant could address that adherence issue by delivering sustained pressure lowering while “eliminating the need for topical drops.” (pienomial.com) The company also linked the new data to earlier first-in-human follow-up. SpyGlass said the phase 1/2 findings reinforce previously released three-year first-in-human results for the same platform. ### How should readers read the pressure-lowering numbers? The control arm also showed a 35% mean intraocular-pressure reduction at the reported 12-month 8 a.m. measurement, a reminder that cataract surgery itself can lower pressure in some patients. (ir.spyglasspharma.com) The company’s release emphasized the commercial-dose arm’s drop-free status and safety profile alongside pressure control, rather than presenting the result as a simple head-to-head pressure advantage over control. Ophthalmology trade reports described the data as positive because the implant combined cataract surgery, drug delivery and pressure management in one procedure. That framing came from company statements and trade coverage, not from a peer-reviewed publication in the sources reviewed here. (ir.spyglasspharma.com) ### What comes next for SpyGlass? SpyGlass said on May 14 that enrollment in registrational phase 3 trials of the BIM-IOL System remains on track, with completion expected in 2027. In the same update, the company said it plans to start BIM-DRS trials in the second half of 2026. (pienomial.com) (ophthalmologytimes.com)